RS58321B1 - Heterociklično jedinjenje - Google Patents

Heterociklično jedinjenje

Info

Publication number
RS58321B1
RS58321B1 RS20190190A RSP20190190A RS58321B1 RS 58321 B1 RS58321 B1 RS 58321B1 RS 20190190 A RS20190190 A RS 20190190A RS P20190190 A RSP20190190 A RS P20190190A RS 58321 B1 RS58321 B1 RS 58321B1
Authority
RS
Serbia
Prior art keywords
cancer
mixture
methyl
compound
added
Prior art date
Application number
RS20190190A
Other languages
English (en)
Serbian (sr)
Inventor
Shizuo Kasai
Takashi Nakahata
Asato Kina
Hideki Hirose
Takeshi Yamasaki
Tohru Yamashita
Yoichi Nishikawa
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of RS58321B1 publication Critical patent/RS58321B1/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/86—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
RS20190190A 2013-10-29 2014-10-28 Heterociklično jedinjenje RS58321B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2013224093 2013-10-29
EP14800152.2A EP3063139B1 (en) 2013-10-29 2014-10-28 Heterocyclic compound
PCT/JP2014/005438 WO2015064083A1 (en) 2013-10-29 2014-10-28 Heterocyclic compound

Publications (1)

Publication Number Publication Date
RS58321B1 true RS58321B1 (sr) 2019-03-29

Family

ID=51932560

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20190190A RS58321B1 (sr) 2013-10-29 2014-10-28 Heterociklično jedinjenje

Country Status (19)

Country Link
US (1) US9120777B2 (enExample)
EP (1) EP3063139B1 (enExample)
JP (1) JP6450755B2 (enExample)
AR (2) AR098215A1 (enExample)
CY (1) CY1121279T1 (enExample)
DK (1) DK3063139T3 (enExample)
ES (1) ES2710657T3 (enExample)
HR (1) HRP20190133T1 (enExample)
HU (1) HUE041792T2 (enExample)
LT (1) LT3063139T (enExample)
PL (1) PL3063139T3 (enExample)
PT (1) PT3063139T (enExample)
RS (1) RS58321B1 (enExample)
SI (1) SI3063139T1 (enExample)
SM (1) SMT201900101T1 (enExample)
TR (1) TR201901986T4 (enExample)
TW (1) TWI668214B (enExample)
UY (1) UY35801A (enExample)
WO (1) WO2015064083A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013122029A1 (ja) * 2012-02-13 2013-08-22 武田薬品工業株式会社 芳香環化合物
US9605000B2 (en) 2013-03-14 2017-03-28 Takeda Pharmaceutical Company Limited Spiro azetidine isoxazole derivatives and their use as SSTR antagonists
JO3442B1 (ar) 2013-10-07 2019-10-20 Takeda Pharmaceuticals Co مضادات ذات نوع فرعي من مستقبل سوماتوستاتين 5 (sstr5)
US20230049619A1 (en) * 2019-12-19 2023-02-16 Universite De Strasbourg Sigma-1 receptor ligands and uses thereof
WO2022052958A1 (en) 2020-09-10 2022-03-17 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
CN116354961B (zh) * 2021-12-27 2025-07-25 中国科学院上海药物研究所 生长抑素受体5拮抗剂及其药物组合物及用途
WO2024204277A1 (ja) 2023-03-27 2024-10-03 株式会社スコヒアファーマ 成長ホルモン分泌促進剤

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5356906A (en) 1989-10-27 1994-10-18 The Du Pont Merck Pharmaceutical Company (N-phthalimidoalkyl) piperidines useful as treatments for psychosis
WO2001096308A1 (en) 2000-06-12 2001-12-20 Eisai Co., Ltd. 1,2-dihydropyridine compounds, process for preparation of the same and use thereof
GB0129260D0 (en) 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
JP4736043B2 (ja) 2003-03-14 2011-07-27 小野薬品工業株式会社 含窒素複素環誘導体およびそれらを有効成分とする薬剤
CN1902171A (zh) 2003-11-10 2007-01-24 舍林股份公司 用作ccr-5拮抗剂的苄醚胺化合物
KR101117931B1 (ko) * 2006-08-15 2012-04-12 에프. 호프만-라 로슈 아게 페닐, 피리딘 및 퀴놀린 유도체
US7862825B2 (en) 2007-02-21 2011-01-04 Mladen Vranic Method of controlling tight blood glucose by somatostatin receptor antagonists
US7799806B2 (en) 2007-04-04 2010-09-21 Hoffmann-La Roche Inc. Substituted n-benzyl piperidines as somatostatin receptor modulators
US20080306116A1 (en) 2007-06-08 2008-12-11 Christ Andreas D Aryloxazole, aryloxadiazole and benzimidazole derivatives
TW200918062A (en) 2007-09-12 2009-05-01 Wyeth Corp Azacyclylisoquinolinone and-isoindolinone derivatives as histamine-3 antagonists
WO2010129729A1 (en) 2009-05-07 2010-11-11 Merck Sharp & Dohme Corp. Substituted spirocyclic amines useful as antidiabetic compounds
US8742110B2 (en) 2010-08-18 2014-06-03 Merck Sharp & Dohme Corp. Spiroxazolidinone compounds
US9000175B2 (en) 2010-11-26 2015-04-07 Lupin Limited Bicyclic GPR119 modulators
US9605000B2 (en) 2013-03-14 2017-03-28 Takeda Pharmaceutical Company Limited Spiro azetidine isoxazole derivatives and their use as SSTR antagonists

Also Published As

Publication number Publication date
LT3063139T (lt) 2019-02-25
CY1121279T1 (el) 2020-05-29
EP3063139A1 (en) 2016-09-07
WO2015064083A1 (en) 2015-05-07
PL3063139T3 (pl) 2019-05-31
AR128158A2 (es) 2024-03-27
UY35801A (es) 2015-06-30
US20150119412A1 (en) 2015-04-30
EP3063139B1 (en) 2018-11-21
JP2016535040A (ja) 2016-11-10
PT3063139T (pt) 2019-02-22
ES2710657T3 (es) 2019-04-26
TR201901986T4 (tr) 2019-03-21
HUE041792T2 (hu) 2019-05-28
TW201542539A (zh) 2015-11-16
TWI668214B (zh) 2019-08-11
DK3063139T3 (en) 2019-03-11
SI3063139T1 (sl) 2019-03-29
US9120777B2 (en) 2015-09-01
SMT201900101T1 (it) 2019-02-28
AR098215A1 (es) 2016-05-18
JP6450755B2 (ja) 2019-01-09
HRP20190133T1 (hr) 2019-03-22

Similar Documents

Publication Publication Date Title
DK3055309T3 (en) Antagonists of somatostatin receptor subtype 5 (SSTR5).
US9346776B2 (en) Fused heterocyclic compound
DK3063139T3 (en) HETEROCYCLIC COMPOUND
IL269347B2 (en) ip6k inhibitors
JP6247697B2 (ja) スピロアゼチジンイソキサゾール誘導体及びそのsstr5アンタゴニストとしての使用
WO2016121782A1 (ja) スルホンアミド化合物
EP3210973A1 (en) Heterocyclic compound